|
- Screens 595 carefully selected genes associated with childhood-onset conditions where early intervention may improve outcomes
- Designed for maternity hospitals, obstetrics practices, newborn care providers, pediatric clinics and families seeking earlier genetic insights from birth
- Expands 3billion's precision medicine platform from rare disease diagnosis into proactive newborn health management
SEOUL, South Korea and AUSTIN, Texas, June 1, 2026 /PRNewswire/ -- 3billion, a global AI-powered genomic diagnostics company, today announced the launch of 3B-NEO, a premium genomic newborn screening (gNBS) service designed to identify genetic risks before symptoms appear and support earlier medical intervention.
3B-NEO was developed in response to growing demand from international healthcare providers and global partners as genomic newborn screening gains momentum worldwide. The service is intended for all newborns and clinically actionable genetic insights focused on conditions where early medical intervention, monitoring, or treatment may meaningfully improve outcomes. Rather than expanding the number of genes analyzed, 3B-NEO was designed to prioritize actionable findings that can support real-world clinical decision-making for physicians and families.
Traditional newborn screening programs primarily rely on biochemical markers and typically assess a limited number of conditions. In contrast, 3B-NEO analyzes 595 carefully selected genes associated with serious childhood-onset disorders where treatment, monitoring, or medical management may improve outcomes. By identifying genetic risks before symptoms emerge, the test can support earlier diagnosis, proactive monitoring, and timely intervention.
The 595 genes panel focuses on conditions that are likely to present during childhood and may benefit from early medical action. These include inherited metabolic disorders, immunologic disorders, neuromuscular diseases, cardiovascular conditions, and other clinically significant pediatric genetic disorders. The service was designed to prioritize actionable information over exhaustive genetic findings, enabling healthcare providers to focus on risks that may influence patient management during infancy and early childhood.
3B-NEO is available in two testing options: a Whole Exome Sequencing (WES)-based standard test and a Whole Genome Sequencing (WGS)-based premium test. Results are typically delivered within approximately two weeks after sample receipt.
The service is designed for hospitals, obstetrics practices, pediatric clinics and families seeking earlier genetic insights for newborns. Healthcare providers can offer 3B-NEO without establishing in-house genomic testing infrastructure, while parents may request testing through participating healthcare providers subject to clinical review and approval.
As genomic newborn screening continues to gain clinical validation through large-scale research initiatives and pilot programs in the United States, Europe, and other regions, demand for earlier genetic risk assessment is growing. 3billion plans to collaborate with healthcare providers globally, including markets where access to advanced genetic testing remains limited but the need for early diagnosis and preventive healthcare continues to increase.
"Genomic newborn screening creates the greatest value when it enables action before symptoms appear," said Changwon Keum, CEO of 3billion. "Advances in genomic medicine are making it increasingly possible to identify health risks early and prepare appropriate medical interventions before irreversible complications develop. Through 3B-NEO, we aim to help healthcare providers and families make earlier, more informed decisions that can improve long-term health outcomes."
The launch of 3B-NEO represents an important step in expanding 3billion's precision medicine platform beyond rare disease diagnosis and into proactive genomic healthcare across the life cycle.
Founded in 2016, 3billion provides AI-powered genomic interpretation and rare disease diagnostic services to healthcare professionals in more than 75 countries and over 800 partner institutions worldwide. The company is expanding its global precision medicine platform from diagnosis toward therapeutic discovery and development.
As part of its U.S. growth strategy, 3billion established its U.S. subsidiary in Austin, Texas, and is preparing local laboratory operations to further support healthcare providers and patients across the United States.
About 3billion
3billion is a global precision medicine company specializing in AI-powered genomic interpretation and rare disease diagnostics. By combining large-scale genomic data with proprietary artificial intelligence technologies, 3billion helps healthcare providers deliver faster and more accurate genetic diagnoses and supports the broader adoption of genomic medicine worldwide.
For more information, visit: 3billion.io/neo and connect with us on LinkedIn, and Instagram.
Media Contact:
ir@3billion.io
Sales Contact:
support@3billion.io
- Screens 595 carefully selected genes associated with childhood-onset conditions where early intervention may improve outcomes
- Designed for maternity hospitals, obstetrics practices, newborn care providers, pediatric clinics and families seeking earlier genetic insights from birth
- Expands 3billion's precision medicine platform from rare disease diagnosis into proactive newborn health management
SEOUL, South Korea and AUSTIN, Texas, June 1, 2026 /PRNewswire/ -- 3billion, a global AI-powered genomic diagnostics company, today announced the launch of 3B-NEO, a premium genomic newborn screening (gNBS) service designed to identify genetic risks before symptoms appear and support earlier medical intervention.
3B-NEO was developed in response to growing demand from international healthcare providers and global partners as genomic newborn screening gains momentum worldwide. The service is intended for all newborns and clinically actionable genetic insights focused on conditions where early medical intervention, monitoring, or treatment may meaningfully improve outcomes. Rather than expanding the number of genes analyzed, 3B-NEO was designed to prioritize actionable findings that can support real-world clinical decision-making for physicians and families.
Traditional newborn screening programs primarily rely on biochemical markers and typically assess a limited number of conditions. In contrast, 3B-NEO analyzes 595 carefully selected genes associated with serious childhood-onset disorders where treatment, monitoring, or medical management may improve outcomes. By identifying genetic risks before symptoms emerge, the test can support earlier diagnosis, proactive monitoring, and timely intervention.
The 595 genes panel focuses on conditions that are likely to present during childhood and may benefit from early medical action. These include inherited metabolic disorders, immunologic disorders, neuromuscular diseases, cardiovascular conditions, and other clinically significant pediatric genetic disorders. The service was designed to prioritize actionable information over exhaustive genetic findings, enabling healthcare providers to focus on risks that may influence patient management during infancy and early childhood.
3B-NEO is available in two testing options: a Whole Exome Sequencing (WES)-based standard test and a Whole Genome Sequencing (WGS)-based premium test. Results are typically delivered within approximately two weeks after sample receipt.
The service is designed for hospitals, obstetrics practices, pediatric clinics and families seeking earlier genetic insights for newborns. Healthcare providers can offer 3B-NEO without establishing in-house genomic testing infrastructure, while parents may request testing through participating healthcare providers subject to clinical review and approval.
As genomic newborn screening continues to gain clinical validation through large-scale research initiatives and pilot programs in the United States, Europe, and other regions, demand for earlier genetic risk assessment is growing. 3billion plans to collaborate with healthcare providers globally, including markets where access to advanced genetic testing remains limited but the need for early diagnosis and preventive healthcare continues to increase.
"Genomic newborn screening creates the greatest value when it enables action before symptoms appear," said Changwon Keum, CEO of 3billion. "Advances in genomic medicine are making it increasingly possible to identify health risks early and prepare appropriate medical interventions before irreversible complications develop. Through 3B-NEO, we aim to help healthcare providers and families make earlier, more informed decisions that can improve long-term health outcomes."
The launch of 3B-NEO represents an important step in expanding 3billion's precision medicine platform beyond rare disease diagnosis and into proactive genomic healthcare across the life cycle.
Founded in 2016, 3billion provides AI-powered genomic interpretation and rare disease diagnostic services to healthcare professionals in more than 75 countries and over 800 partner institutions worldwide. The company is expanding its global precision medicine platform from diagnosis toward therapeutic discovery and development.
As part of its U.S. growth strategy, 3billion established its U.S. subsidiary in Austin, Texas, and is preparing local laboratory operations to further support healthcare providers and patients across the United States.
About 3billion
3billion is a global precision medicine company specializing in AI-powered genomic interpretation and rare disease diagnostics. By combining large-scale genomic data with proprietary artificial intelligence technologies, 3billion helps healthcare providers deliver faster and more accurate genetic diagnoses and supports the broader adoption of genomic medicine worldwide.
For more information, visit: 3billion.io/neo and connect with us on LinkedIn, and Instagram.
Media Contact:
ir@3billion.io
Sales Contact:
support@3billion.io
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
3billion Launches 3B-NEO, a Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions
|
The partnership unites two organizations with New Zealand roots and growing global profiles at a moment when both are expanding their presence on the international stage
SAN FRANCISCO and AUCKLAND, New Zealand, June 5, 2026 /PRNewswire/ -- Ivo, the leading platform for AI contract intelligence, today announced a partnership with New Zealand Football to become the Official Legal AI Partner of the All Whites, New Zealand's men's national team.
The collaboration reflects Ivo's continued connection to its New Zealand origins as the company expands its global footprint. Founded in Auckland and now headquartered in San Francisco, Ivo helps global enterprises, including Meta, Uber, IBM, Shopify, and Mitsubishi Electric, accelerate contract workflows and surface critical business intelligence locked inside their contract portfolios.
As part of the partnership, Ivo branding will appear on the front of the All Whites' training and press kit as the team prepares to compete on the sport's biggest international stage, as well as across select New Zealand Football initiatives. New Zealand Football will exclusively use Ivo's contract intelligence platform to draft, review, and analyze all their teams' agreements.
The announcement arrives alongside a wave of global momentum for Ivo, which has grown ARR sixfold in the last 12 months and has recently opened offices in London and New York.
"As a New Zealand-founded company, we know what it takes to build something and take it to the world stage," said Min-Kyu Jung, CEO and co-founder of Ivo. "Standing with the All Whites as they prepare for one of the most significant moments in the program's history is something we're really proud of."
Andrew Pragnell, Chief Executive of New Zealand Football, said: "Ivo is a real Kiwi success story of a company taking on the world, and that's exactly what we strive to do every time our national teams step onto the field. It's exciting to partner with a New Zealand-founded company experiencing strong global growth while remaining connected to its roots. We look forward to working together and supporting each other's continued success."
About Ivo
Ivo is an enterprise-grade AI-powered contract intelligence platform that enables legal and business teams to move faster, reduce risk, and unlock revenue by turning contracts into actionable business intelligence. Founded in New Zealand and headquartered in San Francisco, Ivo helps organizations surface risk instantly, accelerate negotiation cycles, and remove bottlenecks across the contract lifecycle. Customers include leading global enterprises and high-growth companies across multiple industries.
About New Zealand Football
New Zealand Football oversees the beautiful game in Aotearoa New Zealand. From a player's first experience of football at a young age through the development pathway to national competitions, refereeing, coaching, administration, and ultimately representing New Zealand on the international stage, New Zealand Football supports every level of the game.
Football is the largest team participation sport in the country, with more than 180,000 registered players in 2025.
New Zealand Football manages national men's and women's football, futsal, and eFootball leagues and cup competitions.
As the highest-ranked member association in the Oceania Football Confederation, New Zealand Football runs 10 national team programmes, including the men's national team, the All Whites, and the women's national team, the Ford Football Ferns.
Logo - https://mma.prnasia.com/media2/2995230/Ivo_Logo_Full_Ivy_2x_Logo.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2995231/Tim_Payne_NZF_3a.jpg?p=medium600
The partnership unites two organizations with New Zealand roots and growing global profiles at a moment when both are expanding their presence on the international stage
SAN FRANCISCO and AUCKLAND, New Zealand, June 5, 2026 /PRNewswire/ -- Ivo, the leading platform for AI contract intelligence, today announced a partnership with New Zealand Football to become the Official Legal AI Partner of the All Whites, New Zealand's men's national team.
The collaboration reflects Ivo's continued connection to its New Zealand origins as the company expands its global footprint. Founded in Auckland and now headquartered in San Francisco, Ivo helps global enterprises, including Meta, Uber, IBM, Shopify, and Mitsubishi Electric, accelerate contract workflows and surface critical business intelligence locked inside their contract portfolios.
As part of the partnership, Ivo branding will appear on the front of the All Whites' training and press kit as the team prepares to compete on the sport's biggest international stage, as well as across select New Zealand Football initiatives. New Zealand Football will exclusively use Ivo's contract intelligence platform to draft, review, and analyze all their teams' agreements.
The announcement arrives alongside a wave of global momentum for Ivo, which has grown ARR sixfold in the last 12 months and has recently opened offices in London and New York.
"As a New Zealand-founded company, we know what it takes to build something and take it to the world stage," said Min-Kyu Jung, CEO and co-founder of Ivo. "Standing with the All Whites as they prepare for one of the most significant moments in the program's history is something we're really proud of."
Andrew Pragnell, Chief Executive of New Zealand Football, said: "Ivo is a real Kiwi success story of a company taking on the world, and that's exactly what we strive to do every time our national teams step onto the field. It's exciting to partner with a New Zealand-founded company experiencing strong global growth while remaining connected to its roots. We look forward to working together and supporting each other's continued success."
About Ivo
Ivo is an enterprise-grade AI-powered contract intelligence platform that enables legal and business teams to move faster, reduce risk, and unlock revenue by turning contracts into actionable business intelligence. Founded in New Zealand and headquartered in San Francisco, Ivo helps organizations surface risk instantly, accelerate negotiation cycles, and remove bottlenecks across the contract lifecycle. Customers include leading global enterprises and high-growth companies across multiple industries.
About New Zealand Football
New Zealand Football oversees the beautiful game in Aotearoa New Zealand. From a player's first experience of football at a young age through the development pathway to national competitions, refereeing, coaching, administration, and ultimately representing New Zealand on the international stage, New Zealand Football supports every level of the game.
Football is the largest team participation sport in the country, with more than 180,000 registered players in 2025.
New Zealand Football manages national men's and women's football, futsal, and eFootball leagues and cup competitions.
As the highest-ranked member association in the Oceania Football Confederation, New Zealand Football runs 10 national team programmes, including the men's national team, the All Whites, and the women's national team, the Ford Football Ferns.
Logo - https://mma.prnasia.com/media2/2995230/Ivo_Logo_Full_Ivy_2x_Logo.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2995231/Tim_Payne_NZF_3a.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Kiwi-Born Legal AI Company Ivo Partners with New Zealand Football as Global Expansion Accelerates
